MBD2 and acute myeloid leukemia: For example, the high expression of the methyltransferase DNMT3B was related to poor prognosis in AML patients.31 Myelodysplastic syndrome (MDS) and AML-mesenchymal stem cells (MSCs) displayed global hypomethylation and underexpression of the methyltransferase DNMT1 and the methyl-binding protein UHRF1.32 Changes in the methylation patterns of methyl-binding proteins, MBD2 and MeCP2, were observed in B-chronic lymphocytic leukemia (CLL).33 The recurrent change in DNA methylation profile in AML and ALL could predict patients’ prognosis and treatment efficacy.34